Andrew Murphy Skip to primary navigation Skip to main content
0 item $0.00

Associate Professor Andrew Murphy

Associate Professor Andrew Murphy

Adjunct Associate Professor, Department of Immunology, Monash University | National Heart Foundation Future Leader Fellow | NHMRC Career Development Fellow

+61 3 8532 1292

Associate Professor Andrew Murphy obtained a BSc Biotechnology (Hons) from the Queensland University of Technology (QUT) in Brisbane. He then spent a year working on a commercial project for Professor Zee Upton at QUT for a wound healing company, Tissue Therapies. He then moved to Melbourne do conduct his PhD at the Baker Institute, funded by an industry scholarship from the Swiss biotech company Actelion. During this time he discovered an anti-inflammatory role for HDL on circulating monocytes and neutrophils both published in ATVB (collectively >270 citations).

Upon completing his PhD, Andrew moved to New York to commence a postdoctoral fellowship with one of the world leaders in HDL biology, Professor Alan Tall at Columbia University. During this time, he was funded by a prestigious American Heart Association Fellowship. His work shifted to examine the role of cholesterol efflux pathways on the proliferation and mobilisation of haematopoietic stem cells (HSCs) in the bone marrow. Specifically, he defined a cell intrinsic role for ApoE in regulating HSC proliferation and showed that increased numbers of circulating monocytes resulted in larger lesions, which was published in the Journal of Clinical Investigation. He also discovered the haematopoietic role of the cholesterol transporter ABCG4 in platelet production and atherosclerosis, along with defining an important feedback loop for the thrombopoietin receptor c-MPL, published in Nature Medicine.

Associate Professor Murphy also initiated a number of collaborations in New York, in particular with Professor Ira Goldberg and Professor Edward Fisher (NYU) along with Dr Prabhakara Nagareddy (UAB) to explore the mechanisms of diabetes (hyperglycaemia) on monocyte production. Using the novel glucose-lowering agent (SGLT2 inhibitors) they discovered that lowering blood glucose levels decreased circulating monocyte levels and facilitate atherosclerotic lesion regression. They discovered the damage associated molecular pattern molecules as important mediators of this event. These studies published in Cell Metabolism have trigger an extensive and collaborative research program run by these investigators.

In 2013, Associate Professor Murphy was recruited back to the Institute and was funded by the prestigious Viertel Award from Diabetes Research Trust Australia where he began to build his research team. Associate Professor Murphy is an NHMRC Career Development Fellow and a National Heart Foundation Future Leader Fellow and holds Project Grants from the NHMRC. He currently has over 50 publications including those inNature Medicine, Cell Stem Cell, Cell Metabolism, Journal of Clinical Investigation and European Heart Journal.

Research overview

  • Fundamental process regulating haematopoiesis.
  • Understand multi-organ communication to stimulate haematopoiesis.
  • Determining how the body responds to hyperglycaemic spikes.
  • Exploring if and how inflammatory diseases that are associated with increased cardiovascular risk impair the regression of atherosclerotic lesions.
  • Understanding how enhanced reticulated platelets influence accelerated atherosclerosis in diabetes.
  • Exploring the role of human monocyte subsets in cardiovascular disease.
  • Investigating pathways contributing to foam cell formation in the atherosclerotic lesion.

Achievements, Awards and Grants

Achievements

  • NHMRC Career Development Fellowship and National Heart Foundation Future Leader Fellowship (co-funded, 2015–18)
  • Irvine H. Page Finalist - ATVB|PVD Conference, USA (2015)
  • Inaugural winner of the Sir Laurence Muir Medal for Outstanding Medical Research, Baker IDI (2015)
  • Postdoctoral Research Fellowship, American Heart Association (2011–13)

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more